0000000000054319

AUTHOR

Vicente Bertomeu-gonzalez

0000-0001-5309-0562

showing 43 related works from this author

Effect of insulin on readmission for heart failure following a hospitalization for acute heart failure

2020

AIMS: Type 2 diabetes mellitus (T2DM) is common in patients with heart failure (HF) and is related with worse outcomes. Insulin treatment is associated with sodium and water retention, weight gain, and hypoglycaemia-all pathophysiological mechanisms related to HF decompensation. This study aimed to evaluate the association between insulin treatment and the risk of 1year readmission for HF in patients discharged for acute HF.; METHODS AND RESULTS: We prospectively included 2895 consecutive patients discharged after an episode of acute HF in a single tertiary hospital. Multivariable Cox regression, adapted for competing events, was used to assess the association between insulin treatment and …

medicine.medical_specialtymedicine.medical_treatment030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusOriginal Research ArticlesType 2 diabetes mellitusmedicineDiseases of the circulatory (Cardiovascular) systemDecompensation030212 general & internal medicineOriginal Research ArticleEjection fractionbusiness.industryProportional hazards modelInsulinHazard ratioType 2 Diabetes MellitusAcute heart failureHospital readmissionmedicine.diseaseHeart failureRC666-701Insulin therapyCardiology and Cardiovascular Medicinebusiness
researchProduct

Multicenter and all-comers validation of a score to select patients for manual thrombectomy, the DDTA score.

2021

Background Routine manual thrombectomy (MT) is not recommended in primary percutaneous coronary intervention (P-PCI) but it is performed in many procedures. The objective of our study was validating the DDTA score, designed for selecting patients who benefit most from MT. Methods Observational and multicenter study of all consecutive patients undergoing P-PCI in five institutions. Results were compared with the design cohort and the performance of the DDTA was analyzed in all patients. Primary end-point of the analyses was TIMI 3 after MT; secondary endpoints were final TIMI 3, no-reflow incidence, in-hospital mortality and in-hospital major cardiovascular events (MACE). In-hospital prognos…

medicine.medical_specialtymedicine.medical_treatmentMyocardial Infarction030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionInternal medicineMedicineHumansRadiology Nuclear Medicine and imagingIn patient030212 general & internal medicinecardiovascular diseasesEdetic AcidThrombectomyPrimary angioplastyFramingham Risk Scorebusiness.industryIncidence (epidemiology)Percutaneous coronary interventionGeneral MedicineTreatment OutcomeMulticenter studyCohortCardiology and Cardiovascular MedicinebusinessTIMIMace
researchProduct

Predictive Value of Pro-BNP for Heart Failure Readmission after an Acute Coronary Syndrome

2021

Background: N-terminal pro-brain natural peptide (NT-pro-BNP) is a well-established biomarker of tissue congestion and has prognostic value in patients with heart failure (HF). Nonetheless, there is scarce evidence on its predictive capacity for HF re-admission after an acute coronary syndrome (ACS). We performed a prospective, single-center study in all patients discharged after an ACS. HF re-admission was analyzed by competing risk regression, taking all-cause mortality as a competing event. Results are presented as sub-hazard ratios (sHR). Recurrent hospitalizations were tested by negative binomial regression, and results are presented as incidence risk ratio (IRR). Results: Of the 2133 …

medicine.medical_specialtyAcute coronary syndromemedicine.medical_treatmentheart failurelcsh:Medicine030204 cardiovascular system & hematologyRevascularizationArticleacute coronary syndrome03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusmedicine030212 general & internal medicinecardiovascular diseasesbiologybusiness.industryIncidence (epidemiology)lcsh:RGeneral Medicinemedicine.diseaseTroponinHeart failureRelative riskbiology.proteinCardiologyBiomarker (medicine)businesspro-BNPJournal of Clinical Medicine
researchProduct

Mortality associated with cardiovascular disease in patients with COVID-19

2020

Introducción y objetivos: Las enfermedades cardiovasculares (ECV) se han identificado como un factor de riesgo de mal pronóstico en pacientes con infección por COVID-19. Métodos: Se realizó un metanálisis de estudios actualmente disponibles con la prevalencia de ECV en supervivientes frente a no supervivientes en pacientes con infección por COVID-19 hasta el 16 de julio de 2020. Los análisis se realizaron mediante un modelo de efectos aleatorios y sensibilidad. Se realizaron análisis para identificar posibles fuentes de heterogeneidad o evaluar los efectos de los estudios pequeños. Resultados: Se incluyó a 307.596 pacientes de 16 estudios, de los que 46.321 (15,1%) tenían ECV. La tasa de mo…

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)business.industryMortality rateEnfermedad cardiovascularCOVID-19DiseaseCardiovascular diseasemedicine.diseaseRandom effects modelArticleCoronavirusCVD cardiovascular deseaseInternal medicineDiabetes mellitusMortalidadmedicineRisk of mortalityIn patientMortalityRisk factorCardiology and Cardiovascular MedicinebusinessREC: CardioClinics
researchProduct

Síndrome cardiorrenal en la insuficiencia cardiaca aguda: revisando paradigmas

2015

Resumen El sindrome cardiorrenal se ha definido como la disfuncion simultanea de corazon y rinon. El empeoramiento de la funcion renal en pacientes con insuficiencia cardiaca aguda se ha clasificado como sindrome cardiorrenal tipo 1. En este contexto, el empeoramiento de la funcion renal es un hecho frecuente y se produce como resultado de procesos fisiopatologicos complejos, multifactoriales y no del todo conocidos, que incluyen factores hemodinamicos (hipoperfusion arterial renal y congestion venosa renal) y no hemodinamicos. Tradicionalmente, el empeoramiento de la funcion renal se ha asociado a peor pronostico; sin embargo, algunas observaciones han puesto de manifiesto unos resultados …

business.industryMedicineCardiology and Cardiovascular MedicinebusinessHumanitiesRevista Española de Cardiología
researchProduct

Inspiratory Muscle Training and Functional Electrical Stimulation for Treatment of Heart Failure With Preserved Ejection Fraction: The TRAINING-HF Tr…

2019

Introduction and objectives: Despite the prevalence of heart failure with preserved ejection fraction (HFpEF), there is currently no evidence-based effective therapy for this disease. This study sought to evaluate whether inspiratory muscle training (IMT), functional electrical stimulation (FES), or a combination of both (IMT + FES) improves 12- and 24-week exercise capacity as well as left ventricular diastolic function, biomarker profile, and quality of life in HFpEF. Methods: A total of 61 stable symptomatic patients (New York Heart Association II-III) with HFpEF were randomized (1:1:1:1) to receive a 12-week program of IMT, FES, or IMT + FES vs usual care. The primary endpoint of the st…

MaleQuality of lifemedicine.medical_specialtyAftercareElectric Stimulation Therapy030204 cardiovascular system & hematologyBreathing Exercises03 medical and health sciences0302 clinical medicineOxygen ConsumptionQuality of lifeInternal medicineSurveys and QuestionnairesClinical endpointExercise capacityMedicineFunctional electrical stimulationHumansAerobic capacityAgedHeart FailureExercise Tolerancebusiness.industryInspiratory muscle trainingStroke VolumeGeneral MedicineExercise capacityCombined Modality TherapyTreatment OutcomeHeart failure with preserved ejection fractionEchocardiographySample SizeCardiologyBiomarker (medicine)FemalebusinessHeart failure with preserved ejection fractionPhysical therapy
researchProduct

Sex differences in the management of patients with acute coronary syndrome: A population-based ecological cross-sectional study in Spain

2021

Abstract Introduction and objectives Despite evidence of a reduction in the incidence and mortality of acute coronary syndrome (ACS), some studies have highlighted differences in outcomes between men and women. We aimed to explore sex differences in the management and treatment of patients with ACS in Spain. Methods This ecological cross-sectional study combined ACS data from 10 Spanish registries (54 centres). Meta-regression analysis was performed using aggregated data of baseline characteristics, interventional procedures, treatments, and events that occurred during hospitalization and one-year follow-up. Results Aggregated data from 34 605 patients (75.1% men) was included. ST-segment e…

Acute coronary syndromePercutaneousRevascularization surgerybusiness.industryEcologyCross-sectional studyIncidence (epidemiology)medicine.diseaseDiabetes mellitusmedicineMyocardial infarctionCardiology and Cardiovascular MedicinebusinessKillip classREC: CardioClinics
researchProduct

Usefulness of delta troponin for diagnosis and prognosis assessment of non-ST-segment elevation acute chest pain.

2014

The additional diagnostic and prognostic information provided by delta high-sensitivity troponin T (hs-cTnT) in patients with acute chest pain and hs-cTnT elevation remains unclear.The study group consisted of 601 patients presenting at the emergency department with non-ST-segment elevation acute chest pain and hs-cTnT elevation after two determinations (admission and within the first six hours). Maximum hs-cTnT and delta hs-cTnT (absolute or percentage change between the two measurements) were considered. Cutoff values were optimized using the quartile distribution for the endpoints. The endpoints were diagnostic (significant stenosis in the coronary angiogram) and prognostic (death or rec…

Malemedicine.medical_specialtyChest Pain030204 cardiovascular system & hematologyCritical Care and Intensive Care MedicineChest pain03 medical and health sciences0302 clinical medicineTroponin TInternal medicinemedicineST segmentHumans030212 general & internal medicineMyocardial infarctionAgedTroponin TbiologySurrogate endpointbusiness.industryGeneral MedicineEmergency departmentMiddle Agedmedicine.diseasePrognosisTroponinQuartileCardiologybiology.proteinFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessEuropean heart journal. Acute cardiovascular care
researchProduct

International Normalized Ratio and Mortality Risk in Acute Heart Failure and Nonvalvular Atrial Fibrillation Patients Receiving Vitamin K Antagonists

2019

Introduction and objectives: Heart failure patients with nonvalvular atrial fibrillation (NVAF) on treatment with vitamin K antagonists (VKA) often have suboptimal international normalized ratio (INR) values. Our aim was to evaluate the association between INR values at admission due to acute heart failure and mortality risk during follow-up. Methods: In this observational study, we retrospectively assessed INR on admission in 1137 consecutive patients with acute heart failure and NVAF who were receiving VKA treatment. INR was categorized into optimal values (INR = 2-3, n = 210), subtherapeutic (INR 3, n = 267). Because INR did not meet the proportional hazards assumption for mortality, res…

Maleendocrine systemmedicine.medical_specialtyTime FactorsVitamin KHeart failure030204 cardiovascular system & hematologyVitamin kRisk Assessment03 medical and health sciences0302 clinical medicineRisk FactorsInterquartile rangeCause of DeathThromboembolismhealth services administrationMean Survival TimeInternal medicineAtrial FibrillationmedicineHumansheterocyclic compoundsInternational Normalized Ratiocardiovascular diseasesInternational normalized ratioNormal rangeAgedRetrospective StudiesHeart Failurebusiness.industryIncidencefungiAnticoagulantsAtrial fibrillationGeneral MedicinePrognosismedicine.diseaseAtrial fibrillationSurvival RateSpainHeart failureAcute DiseaseCardiologyFemaleObservational studybusinessFollow-Up StudiesRevista Española de Cardiología (English Edition)
researchProduct

Antigen carbohydrate 125 and brain natriuretic peptide serial measurements for risk stratification following an episode of acute heart failure.

2010

Abstract Background The prognostic utility of combining serial measurements of brain natriuretic peptide (BNP) and antigen carbohydrate 125 (CA125) is largely unknown. The aim of this work is to assess the prognostic utility of serial measurements of BNP, CA125, and their optimal combination for predicting long-term mortality, following a hospitalization for acute heart failure (AHF). Methods and results We analyzed 293 consecutive patients admitted with AHF where CA125 and BNP were measured at discharge (T1) and at the first ambulatory visit (T2: median 31days after discharge). Biomarkers were evaluated as snapshot determinations or as serial changes in absolute, relative or categorical ch…

Malemedicine.medical_specialtymedicine.drug_classCohort StudiesText miningAntigenRisk FactorsInternal medicineNatriuretic Peptide BrainmedicineNatriuretic peptideHumansIntensive care medicineAgedAged 80 and overHeart FailureProportional hazards modelbusiness.industryMiddle AgedBrain natriuretic peptidemedicine.diseaseHeart failureCA-125 AntigenAcute DiseaseCardiologyBiomarker (medicine)FemaleCardiology and Cardiovascular MedicinebusinessBiomarkersCohort studyFollow-Up StudiesInternational journal of cardiology
researchProduct

Twenty-four-hour ambulatory heart rate and organ damage in primary hypertension.

2010

The relationship between basal heart rate (HR) and the occurrence of myocardial ischemia, sudden death, cardiovascular mortality have been described. Therefore, further studies are warranted to evaluate the behaviour of heart rate in different scenarios. We sought to determine whether ambulatory heart rate is associated with the presence of target organ damage (TOD) in hypertensive patients.Crossectional study of essential hypertensive patients in whom a twenty-four hour ambulatory blood pressure monitoring (ABPM) was performed. The relationship between TOD and 24 hour ambulatory heart rate (HR) was analyzed.Five hundred and sixty-six patients with arterial hypertension were included (55.8%…

Malemedicine.medical_specialtyAmbulatory blood pressureCross-sectional studyMyocardial IschemiaBlood PressureSudden deathBrain IschemiaHeart RateRisk FactorsDiabetes mellitusInternal medicineSurveys and QuestionnairesHeart rateInternal MedicinemedicineHumansAntihypertensive Agentsbusiness.industryGeneral MedicineBlood Pressure Monitoring AmbulatoryMiddle Agedmedicine.diseaseBlood pressureCross-Sectional StudiesCardiovascular DiseasesAmbulatoryHypertensionCardiologyFemaleCardiology and Cardiovascular MedicinebusinessDyslipidemiaBlood pressure
researchProduct

Lipid profile, cardiovascular disease and mortality in a Mediterranean high-risk population: The ESCARVAL-RISK study

2017

Introduction The potential impact of targeting different components of an adverse lipid profile in populations with multiple cardiovascular risk factors is not completely clear. This study aims to assess the association between different components of the standard lipid profile with allcause mortality and hospitalization due to cardiovascular events in a high-risk population. Methods This prospective registry included high risk adults over 30 years old free of cardiovascular disease (2008-2012). Diagnosis of hypertension, dyslipidemia or diabetes mellitus was inclusion criterion. Lipid biomarkers were evaluated. Primary endpoints were all-cause mortality and hospital admission due to corona…

Malelcsh:MedicineCoronary Disease030204 cardiovascular system & hematology0302 clinical medicineRisk Factors030212 general & internal medicinelcsh:ScienceStrokeeducation.field_of_studyMultidisciplinarymedicine.diagnostic_testMortality rateAbsolute risk reductionMiddle AgedLipidsHospitalizationStrokeDENSITY-LIPOPROTEIN CHOLESTEROLCardiovascular DiseasesHypertensionObesitatSERUM-LIPIDSFemalelipids (amino acids peptides and proteins)HEALTHAdultmedicine.medical_specialtyELECTRICITY GENERATING AUTHORITYRANDOMIZED CONTROLLED-TRIALSPopulationPREDICTION MODELEVENTS03 medical and health sciencesInternal medicineDiabetes mellitusmedicineMortalitatDiabetes MellitusHumansCORONARY-HEART-DISEASEOLDER-PEOPLEeducationTriglyceridesSistema cardiovascularAgedHDL CHOLESTEROLbusiness.industrylcsh:RCholesterol HDLCholesterol LDLmedicine.diseaseAttributable risklcsh:QLipid profilebusinessDyslipidemia
researchProduct

Efecto pronóstico de una estrategia terapéutica guiada por los valores del antígeno carbohidrato 125 (CHANCE-HF). Diseño del estudio

2015

Resumen Introduccion y objetivos La morbilidad y la mortalidad despues de un ingreso por insuficiencia cardiaca aguda siguen siendo extremadamente elevadas. En este contexto, se ha demostrado que las concentraciones plasmaticas del antigeno carbohidrato 125 muestran correlacion con la gravedad de la sobrecarga hidrica y el riesgo de muerte y reingreso. Los datos preliminares indican un posible papel del antigeno carbohidrato 125 como guia para el tratamiento. El objetivo de este estudio es evaluar el efecto pronostico de una estrategia de tratamiento guiada por el antigeno carbohidrato 125 comparada con el tratamiento estandar en pacientes dados de alta recientemente tras un ingreso por ins…

business.industryMedicineCardiology and Cardiovascular MedicinebusinessHumanitiesRevista Española de Cardiología
researchProduct

Benefit of primary percutaneous coronary interventions in the elderly with ST segment elevation myocardial infarction

2020

Objective Primary percutaneous coronary intervention (P-PCI) has demonstrated its efficacy in patients with ST segment elevation myocardial infarction (STEMI). However, patients with STEMI >= 75 years receive less P-PCI than younger patients despite their higher in-hospital morbimortality. The objective of this analysis was to determine the effectiveness of P-PCI in patients with STEMI >= 75 years. Methods We included 979 patients with STEMI >= 75 years, from the ATencion HOspitalaria del Sindrome coronario study, a registry of 8142 consecutive patients with acute coronary syndrome admitted at 31 Spanish hospitals in 2014-2016. We calculated a propensity score (PS) for the indication of P-P…

MaleTime FactorsPercutaneoussistema de registrosmedicine.medical_treatmenthumanosComorbidityCoronary Artery Disease030204 cardiovascular system & hematologyLogistic regression0302 clinical medicineRecurrenceRisk Factorsevaluación de riesgosST segmentRegistries1506030212 general & internal medicineMyocardial infarctionAged 80 and overancianocoronary intervention (PCI)resultado del tratamientoCardiogenic shockAge FactorsShockstemiTreatment Outcomesurgical procedures operativeCardiologyFemaleAcute coronary syndromeCardiology and Cardiovascular MedicineStemiAcute coronary syndromemedicine.medical_specialtyShock CardiogenicPulmonary EdemaRisk Assessmentacute coronary syndromeedema pulmonar03 medical and health sciencesfactores de tiempoPercutaneous Coronary Interventionchoquecirugía coronaria percutáneaInternal medicinemedicinefactores de riesgoHumanscardiovascular diseasesAgedCoronary intervention (PCI)business.industryPercutaneous coronary interventionmedicine.diseaseSpainPropensity score matchingST Elevation Myocardial InfarctionbusinessrecurrenciaOpen Heart
researchProduct

Improvement in risk stratification with the combination of the tumour marker antigen carbohydrate 125 and brain natriuretic peptide in patients with …

2010

Aim Elevated brain natriuretic peptide (BNP) and tumour marker antigen carbohydrate 125 (CA125) levels have shown to be associated with higher risk for adverse outcomes in patients with acute heart failure (AHF). Nevertheless, no attempt has been made to explore the utility of combining these two biomarkers. We sought to assess whether CA125 adds prognostic value to BNP in predicting 6-month all-cause mortality in patients with AHF. Methods and results We analysed 1111 consecutive patients admitted for AHF. Antigen carbohydrate 125 (U/mL) and BNP (pg/mL) were measured at a median of 72 ± 12 h after instauration of treatment. Antigen carbohydrate 125 and BNP were dichotomized based on propos…

Malemedicine.medical_specialtyendocrine system diseasesHeart diseasemedicine.drug_classKaplan-Meier EstimateGastroenterologyRisk AssessmentAntigenInternal medicineNatriuretic Peptide BrainNatriuretic peptidemedicineHumansTumor markerAgedAged 80 and overHeart Failurebusiness.industryProportional hazards modelMiddle Agedmedicine.diseaseBrain natriuretic peptidePrognosisEndocrinologyHeart failureCA-125 AntigenAcute DiseaseFemaleCardiology and Cardiovascular MedicineRisk assessmentbusinesshormones hormone substitutes and hormone antagonistsBiomarkersEuropean heart journal
researchProduct

Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation: FANTASIIA Study.

2015

Introduction: Atrial fibrillation (AF) is associated with an increased risk of thromboembolic events. Many patients with AF receive chronic anticoagulation, either with vitamin K antagonists (VKAs) or with non-VKA oral anticoagulants (NOACs). We sought to analyze variables associated with prescription of NOAC. Methods: Patients with AF under anticoagulation treatment were prospectively recruited in this observational registry. The sample comprised 1290 patients under chronic anticoagulation for AF, 994 received VKA (77.1%) and 296 NOAC (22.9%). Univariate and multivariate analyses were performed to identify variables associated with use of NOAC. Results: Mean age was 73.8 ± 9.4 years, and 4…

MaleVitamin KClinical Decision-MakingMEDLINEAdministration OralHemorrhage030204 cardiovascular system & hematologyVitamin kanticoagulant treatment03 medical and health sciences0302 clinical medicineClinical decision makingFibrinolytic AgentsAtrial FibrillationmedicineHumansPharmacology (medical)030212 general & internal medicineAgedPharmacologyAged 80 and overbusiness.industrynonvitamin K antagonist oral anticoagulantsAnticoagulantsAtrial fibrillationMiddle Agedmedicine.diseasevitamin K antagonistsIncreased riskAnticoagulant therapyAnesthesiaOral anticoagulantFemaleCardiology and Cardiovascular Medicinebusiness
researchProduct

Carbohydrate Antigen-125–Guided Therapy in Acute Heart Failure

2016

Abstract Objectives This study sought to evaluate the prognostic effect of carbohydrate antigen-125 (CA125)–guided therapy (CA125 strategy) versus standard of care (SOC) after a hospitalization for acute heart failure (AHF). Background CA125 has emerged as a surrogate of fluid overload and inflammatory status in AHF. After an episode of AHF admission, elevated values of this marker at baseline as well as its longitudinal profile relate to adverse outcomes, making it a potential tool for treatment guiding. Methods In a prospective multicenter randomized trial, 380 patients discharged for AHF and high CA125 were randomly assigned to the CA125 strategy (n = 187) or SOC (n = 193). The aim in th…

medicine.medical_specialtyendocrine system diseasesbusiness.industry030204 cardiovascular system & hematologymedicine.diseaseRate ratiofemale genital diseases and pregnancy complicationslaw.inventionClinical trial03 medical and health sciences0302 clinical medicineRandomized controlled triallawHeart failureInternal medicineAmbulatoryCardiovascular agentmedicineClinical endpoint030212 general & internal medicineCardiology and Cardiovascular MedicineIntensive care medicinebusinessCause of deathJACC: Heart Failure
researchProduct

Prognostic Value of Geriatric Conditions Beyond Age After Acute Coronary Syndrome

2016

The aim of the present study was to investigate the prognostic value of geriatric conditions beyond age after acute coronary syndrome. This was a prospective cohort design including 342 patients (from October 1, 2010, to February 1, 2012) hospitalized for acute coronary syndrome, older than 65 years, in whom 5 geriatric conditions were evaluated at discharge: frailty (Fried and Green scales), comorbidity (Charlson and simple comorbidity indexes), cognitive impairment (Pfeiffer test), physical disability (Barthel index), and instrumental disability (Lawton-Brody scale). The primary end point was all-cause mortality. The median follow-up for the entire population was 4.7 years (range, 3-2178 …

Gerontologymedicine.medical_specialtyAcute coronary syndromePhysical disabilityActivities of daily livingFrail ElderlyMyocardial InfarctionComorbidity030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineActivities of Daily LivingmedicineClinical endpointHumansCognitive DysfunctionDisabled PersonsProspective Studies030212 general & internal medicineMyocardial infarctionAcute Coronary SyndromeProspective cohort studyGeriatric AssessmentAgedbusiness.industryHazard ratioAge FactorsGeneral MedicinePrognosismedicine.diseaseComorbiditybusinessMayo Clinic Proceedings
researchProduct

Efecto pronóstico diferencial de la diabetes mellitus tipo 2 en mujeres y varones con insuficiencia cardiaca y fracción de eyección conservada

2020

Resumen Introduccion y objetivos La diabetes mellitus tipo 2 (DM2) es una comorbilidad comun en pacientes con insuficiencia cardiaca (IC) con fraccion de eyeccion conservada (ICFEP). Estudios anteriores han demostrado que las mujeres diabeticas tienen mayor riesgo de desarrollar insuficiencia cardiaca que los hombres. Sin embargo, el pronostico a largo plazo de los pacientes diabeticos con insuficiencia cardiaca en funcion del sexo no se ha explorado ampliamente. En este estudio, nuestro objetivo fue evaluar el impacto diferencial de la DM2 en la mortalidad por todas las causas en hombres frente a mujeres con ICFEP tras un ingreso por IC aguda. Metodos Se incluyeron prospectivamente 1.019 p…

Gynecology03 medical and health sciencesmedicine.medical_specialty0302 clinical medicinebusiness.industrymedicine030204 cardiovascular system & hematologyCardiology and Cardiovascular MedicinebusinessRevista Española de Cardiología
researchProduct

Frailty and other geriatric conditions for risk stratification of older patients with acute coronary syndrome

2014

Background Geriatric conditions may predict outcomes beyond age and standard risk factors. Our aim was to investigate a wide spectrum of geriatric conditions in survivors after an acute coronary syndrome. Methods A total of 342 patients older than 65 years were included. At hospital discharge, 5 geriatric conditions were evaluated: frailty (Fried and Green scores), physical disability (Barthel index), instrumental disability (Lawton-Brody scale), cognitive impairment (Pfeiffer questionnaire), and comorbidity (Charlson and simple comorbidity indexes). The outcomes were postdischarge mortality and the composite of death/myocardial infarction during a 30-month median follow-up. Results Seventy…

MaleGerontologyAcute coronary syndromemedicine.medical_specialtyFrail ElderlyMyocardial InfarctionComorbidityRisk AssessmentCohort StudiesRisk FactorsInternal medicineActivities of Daily LivingmedicineHumansProspective StudiesMyocardial infarctionAcute Coronary SyndromeGeriatric AssessmentAgedProportional Hazards ModelsAged 80 and overHand StrengthReceiver operating characteristicProportional hazards modelbusiness.industryHazard ratioPrognosismedicine.diseaseComorbidityROC CurveArea Under CurveMultivariate AnalysisExercise TestFemaleCognition DisordersCardiology and Cardiovascular MedicineRisk assessmentbusinessCohort studyAmerican Heart Journal
researchProduct

Diuretic Strategies in Acute Heart Failure and Renal Dysfunction: Conventional vs Carbohydrate Antigen 125-guided Strategy. Clinical Trial Design

2017

Abstract Introduction and objectives The optimal treatment of patients with acute heart failure (AHF) and cardiorenal syndrome type 1 (CRS-1) is far from being well-defined. Arterial hypoperfusion in concert with venous congestion plays a crucial role in the pathophysiology of CRS-I. Plasma carbohydrate antigen 125 (CA125) has emerged as a surrogate of fluid overload in AHF. The aim of this study was to evaluate the clinical usefulness of CA125 for tailoring the intensity of diuretic therapy in patients with CRS-1. Methods Multicenter, open-label, parallel clinical trial, in which patients with AHF and serum creatinine ≥ 1.4 mg/dL on admission will be randomized to: a) standard diuretic str…

medicine.medical_specialtymedicine.medical_treatmentWater-Electrolyte ImbalanceRenal functionCardiorenal syndrome030204 cardiovascular system & hematologyPatient Care Planning03 medical and health scienceschemistry.chemical_compound0302 clinical medicineFurosemideInternal medicineHumansMedicine030212 general & internal medicineDiureticsIntensive care medicineHeart FailureCreatinineCardio-Renal Syndromebusiness.industryClinical study designChlorthalidoneMembrane ProteinsGeneral Medicinemedicine.diseasePathophysiologyAcetazolamideClinical trialchemistryCA-125 AntigenCreatinineHeart failureAcute DiseaseCardiologyDiureticbusinessRevista Española de Cardiología (English Edition)
researchProduct

Differential prognostic effect of systolic blood pressure on mortality according to left-ventricular function in patients with acute heart failure.

2009

Aims To evaluate the relationship between systolic blood pressure (SBP) and long-term mortality in patients with acute heart failure (AHF) stratified by ejection fraction (LVEF): reduced (≤40%) vs. preserved (≥50%). Methods and results We studied 1049 consecutive patients admitted with AHF. Systolic blood pressure was determined in the emergency department. Left-ventricular ejection fraction was categorized as ≤40% (n = 288), 41–49% (n = 174), or ≥50% (n = 587). Cox regression analysis was used for multivariable analysis. Mean age and SBP were 73 ± 11 years and 150 ± 36 mmHg, respectively. During a median follow-up of 18 months, 290 deaths (33.1%) were identified. Higher SBP was associated …

Malemedicine.medical_specialtySystoleBlood PressureVentricular Function LeftInternal medicinemedicineHumansIn patientcardiovascular diseasesSystoleAgedProportional Hazards ModelsHeart FailureEjection fractionVentricular functionProportional hazards modelbusiness.industryStroke VolumeStroke volumemedicine.diseasePrognosisBlood pressureTreatment OutcomeHeart failureAcute DiseaseCardiologyFemaleCardiology and Cardiovascular Medicinebusinesscirculatory and respiratory physiologyFollow-Up StudiesEuropean journal of heart failure
researchProduct

Prognostic effect of carbohydrate antigen 125-guided therapy in patients recently discharged for acute heart failure (CHANCE-HF). Study design.

2014

Abstract Introduction and objectives Morbidity and mortality after admission for acute heart failure remain prohibitively high. In that setting, plasma levels of antigen carbohydrate 125 have shown to correlate with the severity of fluid overload and the risk of mortality and readmission. Preliminary data suggests a potential role of antigen carbohydrate 125 to guide therapy. The objective of this study is to evaluate the prognostic effect of an antigen carbohydrate 125-guided management strategy vs standard therapy in patients recently discharged for acute heart failure. Methods This is a multicenter, randomized, single-blind, efficacy trial study of patients recently discharged from acute…

AdultMalemedicine.medical_specialtyRandomizationTime FactorsRisk AssessmentAntigenCause of DeathRisk of mortalityMedicineHumansIn patientSingle-Blind MethodProspective StudiesIntensive care medicineAgedHeart Failurebusiness.industryStandard treatmentDisease ManagementCardiovascular AgentsGeneral MedicineMiddle Agedmedicine.diseasePrognosisPatient DischargeClinical trialSurvival RateSpainHeart failureCA-125 AntigenAcute DiseaseFemalebusinessCarbohydrate antigenBiomarkersFollow-Up StudiesRevista espanola de cardiologia (English ed.)
researchProduct

Entrenamiento de la musculatura inspiratoria y la electroestimulación muscular funcional en el tratamiento de la insuficiencia cardiaca con función s…

2019

SEC 2017: Congreso de las Enfermedades Cardiovasculares Introducción y objetivos No se dispone de tratamientos farmacológicos que demuestren reducir la morbimortalidad asociada en pacientes con insuficiencia cardiaca y función sistólica conservada (IC-FEc). El objetivo del presente estudio fue evaluar si en pacientes con IC-FEc, el entrenamiento de la musculatura inspiratoria (EMI), la electroestimulación muscular funcional (EMF) o la combinación de ambas (EMI + EMF) puede mejorar la capacidad funcional, calidad de vida, parámetros de disfunción diastólica o biomarcadores a las 12 y 24 semanas. Métodos Un total de 61 pacientes estables con IC-FEc (clase funcional de la New York Heart Associ…

heart failure with preserved ejection fractioncapacidad funcionalbusiness.industry030204 cardiovascular system & hematologyinsuficiencia cardiaca con función sistólica conservadaexercise capacity03 medical and health sciences0302 clinical medicinequality of lifecalidad de vidaMedicinephysical therapyCardiology and Cardiovascular MedicinebusinessHumanitiesterapia físicaRevista Española de Cardiología
researchProduct

Razón internacional normalizada y mortalidad de los pacientes con insuficiencia cardiaca y fibrilación auricular tratados con antagonistas de la vita…

2019

Resumen Introduccion y objetivos Los pacientes con insuficiencia cardiaca en tratamiento con antagonistas de la vitamina K (AVK) por fibrilacion auricular no valvular (FANV) a menudo presentan valores alterados de la razon internacional normalizada (INR). El objetivo es evaluar la asociacion entre la INR al ingreso por insuficiencia cardiaca y el riesgo de mortalidad en el seguimiento. Metodos Estudio observacional retrospectivo en el que se evaluo la INR al ingreso de 1.137 pacientes consecutivos con insuficiencia cardiaca aguda en tratamiento con AVK por FANV. Esta se categorizo en: INR en rango optimo (INR = 2-3, n = 210), infraterapeutica (INR 3, n = 267). La asociacion independiente en…

Gynecology03 medical and health sciencesmedicine.medical_specialty0302 clinical medicinebusiness.industrymedicine030204 cardiovascular system & hematologyCardiology and Cardiovascular MedicinebusinessRevista Española de Cardiología
researchProduct

Quality of Anticoagulation With Vitamin K Antagonists

2015

Background Vitamin K antagonists (VKA) have a narrow therapeutic range, and literature analysis reveals poor quality of anticoagulation control. We sought to assess the prevalence of poor anticoagulant control in patients under VKA treatment in the prevention of stroke for atrial fibrillation (AF). Hypothesis Control of anticoagulation with VKA is inadequate in a high percentage of patients with AF. Methods Patients with AF under VKA treatment were prospectively recruited in this observational registry. The sample comprised 948 patients. The estimated time spent in the therapeutic range (TTR) was calculated, and variables related with a TTR >65% were analyzed. Results Mean age was 73.8 ± 9.…

medicine.medical_specialtybusiness.industryAtrial fibrillationGeneral MedicineOdds ratiomedicine.diseaseLower riskComorbidityConfidence intervalSurgeryInternal medicinemedicineLiver functionCardiology and Cardiovascular MedicinebusinessProspective cohort studyStrokeClinical Cardiology
researchProduct

A practical approach with outcome for the prognostic assessment of non-ST-segment elevation chest pain and normal troponin.

2007

Patients with non-ST-elevation chest pain constitute a heterogeneous population. Our aim is to compare the outcome of patients with chest pain, non-ST-segment deviation, and normal troponin, categorized using a risk score, with that of patients with ST depression or troponin increase. A total of 1,449 patients with non-ST-elevation chest pain were evaluated. A validated risk score (using pain characteristics and risk factors) was applied to patients without ST depression or troponin increase. Accordingly, 4 risk categories were defined: group 1, no troponin increase, no ST depression, and risk score3 points (n = 633); group 2, no troponin increase, no ST depression, but risk scoreor = 3 poi…

Malemedicine.medical_specialtyChest painSeverity of Illness IndexAngina PectorisRisk categoryRisk FactorsInternal medicinemedicineMyocardial RevascularizationST segmentHumansAgedST depressionFramingham Risk Scorebiologybusiness.industryMiddle AgedPrognosisTroponinSurvival AnalysisTroponinHeterogeneous populationTreatment OutcomeSpainbiology.proteinCardiologyFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessEmergency Service HospitalFollow-Up StudiesThe American journal of cardiology
researchProduct

Differential mortality association of loop diuretic dosage according to blood urea nitrogen and carbohydrate antigen 125 following a hospitalization …

2012

Recent observations in chronic stable heart failure suggest that high-dose loop diuretics (HDLDs) have detrimental prognostic effects in patients with high blood urea nitrogen (BUN), but recent findings have also indicated that diure- tics may improve renal function. Carbohydrate antigen 125 (CA125) has been shown to be a surrogate of systemic congestion. We sought to explore whether BUN and CA125 modulate the mortality risk associated with HDLDs following a hospitalization for acute heart failure (AHF). Methods and results We analysed 1389 consecutive patients discharged for AHF. CA125 and BUN were measured at a mean of 72+12 h after admission. HDLDs (≥120 mg/day in furosemide equivalent d…

Malemedicine.medical_specialtymedicine.drug_classRenal functionGastroenterologyRisk AssessmentLoop diureticsBlood Urea NitrogenCohort StudiesSodium Potassium Chloride Symporter InhibitorsFurosemideInternal medicinemedicineHumansProspective StudiesMortalityProspective cohort studyBlood urea nitrogenAgedAged 80 and overHeart Failurebusiness.industryHazard ratioFurosemideAcute heart failureLoop diureticMiddle Agedmedicine.diseaseConfidence intervalfemale genital diseases and pregnancy complicationsHospitalizationBlood urea nitrogenEndocrinologyCarbohydrate antigen 125Heart failureCA-125 AntigenAcute DiseaseFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugFollow-Up StudiesEuropean journal of heart failure
researchProduct

Predictive validity of the risk SCORE model in a Mediterranean population with dyslipidemia.

2019

Background and aims: Cholesterol treatment for the primary prevention of cardiovascular disease is based on cardiovascular risk, as assessed by the SCORE (Systematic COronary Risk Evaluation) scale. This study aimed to assess the predictive value and clinical utility of the SCORE scale for preventing cardiovascular events and all-cause mortality in people with dyslipidemia and no lipid-lowering treatment. Methods: Patients with dyslipidemia and no lipid-lowering treatment were included from the ESCARVAL-RISK cohort. Cardiovascular risk was calculated by means of the SCORE scale. All deaths and cardiovascular events were recorded for up to five years of follow-up. We calculated sensitivity, …

0301 basic medicinePredictive validityAdultMalemedicine.medical_specialtyTime FactorsPopulationHypercholesterolemia030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciences0302 clinical medicinePredictive Value of TestsRisk FactorsInternal medicineDiabetes mellitusSCOREmedicineHumansProspective StudiesRegistrieseducationAgededucation.field_of_studyFramingham Risk Scorebusiness.industryReproducibility of ResultsMiddle Agedmedicine.diseaseCardiovascular diseaseCardiovascular riskPrognosis030104 developmental biologyCardiovascular DiseasesSpainCohortDisease ProgressionFemaleMetabolic syndromeCardiology and Cardiovascular MedicinebusinessDyslipidemiaKidney diseaseAtherosclerosis
researchProduct

Estrategias diuréticas en insuficiencia cardiaca aguda con disfunción renal: terapia convencional frente a guiada por el antígeno carbohidrato 125. D…

2017

Resumen Introduccion y objetivos El tratamiento optimo de pacientes con insuficiencia cardiaca aguda (ICA) y sindrome cardiorrenal tipo 1 (SCR-1) no esta bien definido. La hipoperfusion arterial y la congestion venosa tienen un papel fundamental en la fisiopatologia del SCR-1. El antigeno carbohidrato 125 (CA125) ha emergido como marcador indirecto de sobrecarga de volumen en la ICA. El objetivo de este estudio es evaluar la utilidad del CA125 para el ajuste del tratamiento diuretico de pacientes con SCR-1. Metodos Ensayo clinico multicentrico, abierto y paralelo, que incluye a pacientes con ICA y creatinina ≥ 1,4 mg/dl al ingreso, aleatorizados a: a)  estrategia convencional: titulacion ba…

03 medical and health sciences0302 clinical medicinebusiness.industryMedicine030212 general & internal medicine030204 cardiovascular system & hematologyCardiology and Cardiovascular MedicinebusinessHumanitiesRevista Española de Cardiología
researchProduct

Limitaciones del blush miocárdico para el análisis de la perfusión miocárdica en pacientes con infarto agudo de miocardio y flujo TIMI 3

2006

Introduccion y objetivos Analizamos la variabilidad en la medicion del indice angiografico de blush entre un hospital universitario y un laboratorio central independiente, asi como su correlacion con la perfusion analizada mediante ecocardiografia miocardica con contraste intracoronario (EMC) y con la funcion ventricular a los 6 meses Metodos Se incluyo en el estudio a 40 pacientes con un primer infarto agudo de miocardio con elevacion del segmento ST, enfermedad de un vaso y arteria relacionada con el infarto abierta. La perfusion se cuantifico por angiografia (mediana quinto dia, rango de 3-7) mediante el blush miocardico en nuestro laboratorio y en un laboratorio central independiente. S…

business.industryMedicineCardiology and Cardiovascular MedicinebusinessHumanitiesRevista Española de Cardiología
researchProduct

A new risk score to assess atrial fibrillation risk in hypertensive patients (ESCARVAL-RISK Project.

2020

AbstractThis study aimed to assess atrial fibrillation (AF) incidence and predictive factors in hypertensive patients and to formulate an AF risk assessment score that can be used to identify the patients most likely to develop AF. This was a cohort study of patients recruited in primary healthcare centers. Patients aged 40 years or older with hypertension, free of AF and with no previous cardiovascular events were included. Patients attended annual visits according to clinical practice until the end of study or onset of AF. The association between AF incidence and explanatory variables (age, sex, body mass index, medical history and other) was analyzed. Finally, 12,206 patients were includ…

AdultMaleRiskmedicine.medical_specialtyTime FactorsCardiologylcsh:Medicine030204 cardiovascular system & hematologyRisk AssessmentArticleCohort Studies03 medical and health sciencesSex Factors0302 clinical medicineInternal medicineAtrial FibrillationmedicineHumansObesity030212 general & internal medicinelcsh:ScienceAgedHeart FailureMultidisciplinaryFramingham Risk Scorebusiness.industryIncidenceIncidence (epidemiology)lcsh:RHazard ratioAge FactorsAtrial fibrillationMiddle Agedmedicine.diseaseConfidence intervalRisk factorsResearch DesignHypertensionFemalelcsh:QbusinessRisk assessmentBody mass indexFollow-Up StudiesForecastingCohort study
researchProduct

Beneficios del tratamiento con estatinas según los valores plasmáticos del antígeno carbohidrato 125 tras un ingreso por insuficiencia cardiaca aguda

2011

Introduccion y objetivos La utilidad de las estatinas en pacientes con insuficiencia cardiaca es motivo de controversia. Bajo la hipotesis de que el tratamiento con estatinas seria util en los pacientes con insuficiencia cardiaca y mayor actividad inmunoinflamatoria, pretendimos conocer si la elevacion del antigeno carbohidrato 125, un biomarcador asociado a la congestion sistemica y actividad inflamatoria, identificaria a los que se beneficiarian, en cuanto a mortalidad, del tratamiento con estatinas tras un ingreso por insuficiencia cardiaca aguda. Metodos Analizamos a 1.222 pacientes consecutivos ingresados por insuficiencia cardiaca aguda. El antigeno carbohidrato 125 se determino duran…

Gynecologymedicine.medical_specialtybusiness.industrymedicineCardiology and Cardiovascular MedicinebusinessRevista Española de Cardiología
researchProduct

Heart rate in acute heart failure, lower is not always better.

2010

Aged 80 and overHeart FailureMalemedicine.medical_specialtybusiness.industryMiddle Agedmedicine.diseaseHeart RateRisk FactorsInternal medicineHeart failureHeart rateAcute DiseasemedicineCardiologyHumansFemaleCardiology and Cardiovascular MedicineIntensive care medicinebusinessAgedFollow-Up StudiesProportional Hazards ModelsInternational journal of cardiology
researchProduct

Los desafíos del profesorado clínico en la educación médica

2019

Resumen: Antecedentes: La enseñanza clínica en la educación médica tiene una particularidad única: el contexto clínico. Este estudio tiene como objetivo analizar las principales barreras de la enseñanza clínica en una facultad joven de Medicina de España. Métodos: Se trata de un estudio transversal descriptivo en el que se solicitó a todos los profesores clínicos (todos ellos profesores asociados) de una facultad joven de Medicina que respondieran a un cuestionario en línea, anónimo y voluntario sobre aspectos de carga asistencial, promoción de la investigación clínica y reconocimiento de sus carreras profesionales. Resultados: Sesenta y un profesores (42%) respondieron al cuestionario. Los…

lcsh:R5-920Clinical teachingEducación médica públicaEnseñanza clínicaPublic medical educationGeneral Medicinelcsh:L7-991lcsh:Medicine (General)lcsh:Education (General)EducationAccreditationAcreditaciónEducación Médica
researchProduct

Prognostic differences between routine invasive and conservative strategies for the management of high-risk, non-ST segment acute coronary syndromes:…

2007

Abstract Background The optimal revascularization strategy for non-ST elevation acute coronary syndromes (NSTE-ACS) remains controversial, especially in a real world context. The objective of this work was to assess differences at 1 year in all-cause mortality and the composite endpoint of mortality or acute myocardial infarction (MI) between two management strategies for NSTE-ACS: a conservative strategy (CS) versus a routine invasive strategy (RIS). Methods Of 799 consecutive patients admitted to our institution, 369 were treated with CS (from January 2001 to October 2002); 430 patients admitted with the same diagnosis were treated with RIS (from November 2002 to November 2004). A propens…

Relative risk reductionmedicine.medical_specialtyeducation.field_of_studybusiness.industrymedicine.medical_treatmentMortality ratePopulationContext (language use)Revascularizationmedicine.diseaseLower riskMedication prescriptionSurgeryInternal medicineInternal MedicinemedicineMyocardial infarctionbusinesseducationEuropean Journal of Internal Medicine
researchProduct

Differential prognostic impact of type 2 diabetes mellitus in women and men with heart failure with preserved ejection fraction

2020

Introduction and objectives Type 2 diabetes mellitus (DM2) is a common comorbidity in patients with heart failure (HF) with preserved ejection fraction (HFpEF). Previous studies have shown that diabetic women are at higher risk of developing HF than men. However, the long-term prognosis of diabetic HFpEF patients by sex has not been extensively explored. In this study, we aimed to evaluate the differential impact of DM2 on all-cause mortality in men vs women with HFpEF after admission for acute HF. Methods We prospectively included 1019 consecutive HFpEF patients discharged after admission for acute HF in a single tertiary referral hospital. Multivariate Cox regression analysis was used to …

Malemusculoskeletal diseasesmedicine.medical_specialtyComorbidity030204 cardiovascular system & hematologydiiferencias entre sexos03 medical and health sciencesDiabetes mellitus0302 clinical medicineInterquartile rangeInternal medicineSex differencesRisk of mortalitymedicineHumansWomenMortalityAgedAged 80 and overHeart FailureEjection fractionProportional hazards modelbusiness.industryHazard ratioDiferencias entre sexosStroke VolumeMujeresGeneral MedicinePrognosisInsuficiencia cardiaca con fracción de eyección preservadamedicine.diseaseComorbidityHeart failure with preserved ejection fractionDiabetes Mellitus Type 2MortalidadCohortFemalebusinessHeart failure with preserved ejection fractionRevista Española de Cardiología (English Edition)
researchProduct

Anticoagulation prescription in atrial fibrillation.

2011

We seek to assess the factors associated with the anticoagulation prescription in a cohort of patients with atrial fibrillation (AF) collected from out-patient clinics.A total of 1524 patients with a history of AF were collected from out-patients clinics. CHADS(2), CHA(2)DS(2)-VASc and HAS-BLED scores were calculated in every patient. Variables associated with anticoagulant treatment prescription were analyzed in univariant and multivariant models.Most patients received either anticoagulant (62%) or antiplatelet treatment (37%). Anticoagulation rates increased among higher CHADS(2) and CHA(2)DS(2)-VASc score values. A logistic regression model was performed to assess the variables associate…

Malemedicine.medical_specialtymedicine.drug_classHemorrhageLogistic regressionAmbulatory Care FacilitiesRisk FactorsInternal medicineAtrial FibrillationmedicineHumansPharmacology (medical)Medical prescriptionPractice Patterns Physicians'AgedPharmacologyAged 80 and overbusiness.industryAnticoagulantAnticoagulantsAtrial fibrillationThrombosisGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseLogistic ModelsAnticoagulant therapyConcomitantCohortMultivariate AnalysisCardiologyFemalebusinessPlatelet Aggregation InhibitorsExpert opinion on pharmacotherapy
researchProduct

Lipid profile, cardiovascular disease and mortality in a Mediterranean high-risk population: The ESCARVAL-RISK study

2018

Introduction The potential impact of targeting different components of an adverse lipid profile in populations with multiple cardiovascular risk factors is not completely clear. This study aims to assess the association between different components of the standard lipid profile with all-cause mortality and hospitalization due to cardiovascular events in a high-risk population. Methods This prospective registry included high risk adults over 30 years old free of cardiovascular disease (2008–2012). Diagnosis of hypertension, dyslipidemia or diabetes mellitus was inclusion criterion. Lipid biomarkers were evaluated. Primary endpoints were all-cause mortality and hospital admission due to coron…

AdultMaleDeath RatesEndocrine Disorderslcsh:MedicineBlood PressureCoronary DiseaseCardiovascular Medicine030204 cardiovascular system & hematologyBiochemistryVascular Medicine03 medical and health sciencesEndocrinology0302 clinical medicinePopulation MetricsRisk FactorsMalalties ComplicacionsMortalitatMedicine and Health SciencesDiabetes MellitusHumans030212 general & internal medicinelcsh:ScienceTriglyceridesSistema cardiovascularAgedMultidisciplinaryPopulation BiologyCholesterol HDLlcsh:RBiology and Life SciencesCorrectionCholesterol LDLMiddle AgedLipidsHospitalizationStrokeCholesterolNephrologyCardiovascular DiseasesMetabolic DisordersHypertensionlipids (amino acids peptides and proteins)Femalelcsh:QBiomarkersResearch ArticlePLOS ONE
researchProduct

Hemorrhage in patients under oral anticoagulation for atrial fibrillation. The other side of the coin

2019

Abstract Introduction and objectives Oral anticoagulation therapy is prescribed to most patients with atrial fibrillation. The main limitation of anticoagulant treatment is the occurrence of bleeding episodes. We sought to assess the type of hemorrhages and mortality in patients anticoagulated for nonvalvular atrial fibrillation. Methods Observational retrospective study analyzing 2 081 138 hospitalization reports from 2014 corresponding to 151 hospitals of the Spanish National Health System. Patients were selected with the diagnosis of hemorrhage, nonvalvular atrial fibrillation, and oral anticoagulation. Results A total of 5783 hospitalizations were analyzed. Most hemorrhages were digesti…

National healthmedicine.medical_specialtyBleeding episodeseducation.field_of_studybusiness.industryPopulationRetrospective cohort studyAtrial fibrillationmedicine.diseaseAnticoagulant therapyInternal medicinemedicineIn patientCardiology and Cardiovascular MedicineeducationbusinessOral anticoagulationREC: CardioClinics
researchProduct

New Risk Score for Patients With Acute Chest Pain, Non-ST-Segment Deviation, and Normal Troponin Concentrations

2005

Objectives The purpose of this research was to develop a risk score for patients with chest pain, non-ST-segment deviation electrocardiogram (ECG), and normal troponin levels. Background Prognosis assessment in this population remains a challenge. Methods A total of 646 consecutive patients were evaluated by clinical history (risk factors and chest pain score according to pain characteristics), ECG, and early exercise testing. ST-segment deviation and troponin elevation were exclusion criteria. The primary end point was mortality or myocardial infarction at one year. The secondary end point was mortality, myocardial infarction, or urgent revascularization at 14 days (similar to the Thrombol…

medicine.medical_specialtyeducation.field_of_studyFramingham Risk Scorebusiness.industryPopulationmedicine.diseaseChest painAnginaInternal medicinemedicineCardiologyMyocardial infarctionMyocardial infarction diagnosisRisk factormedicine.symptombusinesseducationCardiology and Cardiovascular MedicineTIMIJournal of the American College of Cardiology
researchProduct

CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction

2020

BACKGROUND: The optimal diuretic treatment strategy for patients with acute heart failure and renal dysfunction remains unclear. Plasma carbohydrate antigen 125 (CA125) is a surrogate of fluid overload and a potentially valuable tool for guiding decongestion therapy. The aim of this study was to determine if a CA125-guided diuretic strategy is superior to usual care in terms of short-term renal function in patients with acute heart failure and renal dysfunction at presentation. METHODS: This multicenter, open-label study randomized 160 patients with acute heart failure and renal dysfunction into 2 groups (1:1). Loop diuretics doses were established according to CA125 levels in the CA125-gui…

Maleendocrine system diseasesPREDICTIONmedicine.medical_treatmentUrine030204 cardiovascular system & hematologyKidney Function TestsCONGESTIONBiomarker guided-therapy0302 clinical medicineSodium Potassium Chloride Symporter InhibitorsFurosemideNatriuretic peptideMedicineRenal Insufficiency030212 general & internal medicinePrecision MedicineANTIGEN CARBOHYDRATE 125Aged 80 and overFurosemideGeneral MedicineDiuretic treatmentEUROPEAN-SOCIETYClinical trialFemaleTRIALmedicine.drugmedicine.medical_specialtyRenal failureSTRATEGIESmedicine.drug_classUrologyRenal function03 medical and health sciencesHumansIn patientAgedHeart FailureSERUM CREATININENATRIURETIC PEPTIDEbusiness.industryMORTALITYMembrane ProteinsAcute heart failuremedicine.diseaseClinical trialCarbohydrate antigen 125CA-125 AntigenHeart failureDiuretic treatmentDiureticbusinessCARDIORENAL SYNDROME
researchProduct

Cardiorenal Syndrome in Acute Heart Failure: Revisiting Paradigms

2015

A B S T R A C T Cardiorenal syndrome has been defined as the simultaneous dysfunction of both the heart and the kidney. Worsening renal function that occurs in patients with acute heart failure has been classified as cardiorenal syndrome type 1. In this setting, worsening renal function is a common finding and is due to complex, multifactorial, and not fully understood processes involving hemodynamic (renal arterial hypoperfusion and renal venous congestion) and nonhemodynamic factors. Traditionally, worsening renal function has been associated with worse outcomes, but recent findings have revealed mixed and heterogeneous results, perhaps suggesting that the same phenotype represents a dive…

Heart Failuremedicine.medical_specialtyKidneyCardio-Renal Syndromebusiness.industryHemodynamicsHemodynamicsRenal functionGeneral MedicineCardiorenal syndromeurologic and male genital diseasesmedicine.diseasePathophysiologymedicine.anatomical_structureHeart failureAcute DiseasemedicineHumansDecompensationIntensive care medicinebusinessPerfusionRevista Española de Cardiología (English Edition)
researchProduct